The Correlation between the Numerical Status of Th22 Cells and Serum Level of IL-22 with Severity of Ulcerative Colitis

  • Abbas Arj Department of Gastroentrology, Kashan University of Medical Sciences, Kashan, Iran
  • Mohsen Razavizadeh Department of Gastroentrology, Kashan University of Medical Sciences, Kashan, Iran
  • Hanieh Mohammadi Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
  • Hassan Nikoueinejad Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Hossein Akbari Department of Community Medicine, Kashan University of medical sciences, Kashan, Iran
Keywords: Interleukin-22, Th22 cells, Ulcerative colitis


Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease, yet its etiology as well as pathogenesis remain poorly understood. There is increasing evidence that aberrant expression of CD4+T lymphocytes plays an essential role in the progression of different pathologies such as UC. This study aimed to evaluate the circulatory frequency of T-helper 22 (Th22), a subset of CD4+ T cells, and serum level of its signature cytokine, IL-22, in patients with UC. Blood samples from 30 patients with UC and 30 controls (n=30) were tested for IL-22 level and circulatory Th22-cell count by ELISA and Flow cytometric analysis, respectively. Our results revealed higher serum level of IL-22 as well as circulatory frequency of Th22 cells in patients with UC compared to those in healthy controls. Notably, effective factors on severity of the disease were age, Th22, IL-22, ESR and CRP. We conclude that elevated circulating Th22 cells and their signature cytokine, IL-22, may be implicated in the pathogenesis of UC. These findings may provide preliminary experimental clues for the development of new therapies for UC and its severity judgment.


1. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis 2010; 11(2):76-82.2. Choi P, Zelig M. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35(7):950-4.3. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005; 206(1):296-305.4. Zhang N, Pan H-F, Ye D-Q. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 2011; 353(1-2):41-6.5. Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K, et al. Involvement of the IL-22/REG Iα axis in ulcerative colitis. Lab Invest 2010; 90(3):496-505.6. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36(5):1309-23.7. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21(2):241-54.8. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010; 21(5):365-79.9. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14(3):282-9.10. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14(3):275-81.11. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174(6):3695-702.12. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin‐22 in collagen‐induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009; 60(2):390-5.13. Teraki Y, Sakurai A, Izaki S. IL-13/IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis. J Allergy Clin Immunol 2013; 132(4):971-4.14. Li L-J, Gong C, Zhao M-H, Feng B-S. Role of interleukin-22 in inflammatory bowel disease. World journal of gastroenterology: WJG. 2014; 20(48):18177.15. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10(8):857-63.16. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119(12):3573-85.17. Leung J, Davenport M, Wolff M, Wiens K, et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014; 7(1):124-33.18. Korolkova OY, Myers JN, Pellom ST, Wang L, M'Koma AE. Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn's colitides. Clin Med Insights Gastroenterol 2015; 8:29-44.19. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007; 76(9):1323-30.20. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140(6):1756-67.21. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, et al. Expression of interleukin‐22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52(4):1037-46.22. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012; 2012(1):306-12.23. Lin S, Yang X, Liang D, Zheng SG. Treg cells: a potential regulator for IL-22 expression. Int J Clin Exp Pathol 2014; 7(2):474-80.24. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445(7128):648-51.25. Wolk K, Witte E, Hoffmann U, Doecke W-D, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J Immunol 2007; 178(9):5973-81.26. Chan YR, Chen K, Duncan SR, Lathrop KL, Latoche JD, Logar AJ, et al. Patients with cystic fibrosis have inducible IL-17+ IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol 2013; 131(4):1117-29.27. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13(10):1173-5.28. Scriba TJ, Kalsdorf B, Abrahams D-A, Isaacs F, Hofmeister J, Black G, et al. Distinct, specific IL-17-and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008; 180(3):1962-70.29. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290(4):G827-G38.30. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118(2):534-44.31. Ma H-L, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118(2):597-607.

How to Cite
Arj A, Razavizadeh M, Mohammadi H, Nikoueinejad H, Akbari H. The Correlation between the Numerical Status of Th22 Cells and Serum Level of IL-22 with Severity of Ulcerative Colitis. ijaai. 17(1):78-4.
Original Article(s)